FADD (N188) polyclonal Antibody | BS1399

FADD (N188) polyclonal Antibody | BS1399 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Mouse,Rat

Application: WB IHC

Application Range: WB: 1:500~1:1000 IHC: 1:50~1:200

Background: In contrast to growth factors which promote cell proliferation, FAS ligand (FAS-L) and the tumor necrosis factors (TNFs) rapidly induce apoptosis. Cellular response to FAS-L and TNF is mediated by structurally related receptors containing a conserved “death domain” and belonging to the TNF receptor superfamily. TRADD, FADD and RIP are FAS/TNF-R1 interacting proteins that contain a death domain homologous region (DDH) . TRADD (TNF-R1-associated death domain) and FADD (FAS-associated death domain) associate with the death domains of both FAS and TNF-R1 via their DDH regions. Overexpression of TRADD leads to NFκB activation and apoptosis in the absence of TNF. Overexpression of FADD causes apoptosis, which can be blocked by the cow pox protein CrmA, suggesting that FADD lies upstream of ICE and possibly other serine proteases. The receptor interacting protein, RIP, associates with FAS exclusively via its DDH and this association is abrogated in lpr mutants. Unlike TRADD and FADD, RIP contains a putative amino-terminal kinase domain.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: FADD (N188) polyclonal Antibody detects endogenous levels of FADD protein.

Molecular Weight: ~ 28 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: FAS-associated death domain protein; FAS-associating death domain-containing protein; Growth-inhibiting gene 3 protein; Mediator of receptor induced toxicity; Protein FADD; FADD; MORT1; GIG3

Immunogen: Synthetic peptide, corresponding to amino acids 150-200 of Human FADD.

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: